180 Life Sciences : Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology - Form 8-K

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology




·
... | May 2, 2022

Related Keywords

United States ,Jagdeep Nanchahal ,Suzanne Messere ,David Schull ,Jason Assad ,Stern Investor Relations Inc ,University Of Oxford ,Life Sciences Corp ,Hebrew University ,Nasdaq ,Exchange Commission ,Department Of Health ,Health Innovation Challenge Fund Wellcome ,Life Sciences ,Oxford University ,Stanford University ,Oxford Announce Publication ,Positive Phase ,Disease Study Results ,Health Innovation Challenge Fund ,Wellcome Trust ,Social Care ,James Woody ,Chief Executive Officer ,Professor Jagdeep Nanchahal ,Clinical Advisory Board ,Anti Tumour Necrosis Factor Therapy ,Early Stage Dupuytren ,Randomised Dose Response Proof ,Concept Phase ,Private Securities Litigation Reform Act ,Investigational New Drug ,Annual Report ,Investor Relations ,180 Life Sciences Corp Stock Exchange ,News ,Information ,Press Release ,80 ,Life ,Ciences ,End ,University ,F ,Oxford ,Nnounce ,Publication ,Positive ,Hase ,Tb ,Disease ,Study ,Results ,N ,The ,Ancet Atnf Us68236v1044 ,